Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

Biotechnology • Healthcare • Edmonton, AB, United States • AUPH (NGM)

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

250 744 2487 #140, 14315 – 118 Avenue, Edmonton, AB T5L 4S6, Canada

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Riding the Biotech Wave with 8.93% Potential Upside - DirectorsTalk Interviews
DirectorsTalk Interviews • Jan 6
Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH) - Seeking Alpha
Seeking Alpha • Dec 16
What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Yahoo Finance • Dec 5
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - Zacks Investment Research
Zacks Investment Research • Dec 2
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Squarepoint Ops LLC - MarketBeat
MarketBeat • Dec 16

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Aurinia Pharmaceuticals Inc. had layoffs?
No layoff events have been recorded for Aurinia Pharmaceuticals Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Aurinia Pharmaceuticals Inc. have?
Aurinia Pharmaceuticals Inc. has approximately 130 employees.
What industry is Aurinia Pharmaceuticals Inc. in?
Aurinia Pharmaceuticals Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Aurinia Pharmaceuticals Inc. a publicly traded company?
Yes, Aurinia Pharmaceuticals Inc. is publicly traded under the ticker symbol AUPH on the NGM. The company has a market capitalization of approximately $2.14 billion.
Where is Aurinia Pharmaceuticals Inc. headquartered?
Aurinia Pharmaceuticals Inc. is headquartered in Edmonton, AB, United States at #140, 14315 – 118 Avenue, Edmonton, AB T5L 4S6, Canada.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.